Wegovy 1.0 mg: what the evidence says about this dose

What the STEP 1 trial tells us about the escalation phase

The STEP 1 trial, which randomised 1,961 adults with obesity or overweight and at least one weight-related condition, showed that participants lost weight progressively across the full 68-week study period, not only once they reached the 2.4 mg maintenance dose. The full STEP 1 paper in the New England Journal of Medicine reported an average body-weight reduction of around 15% by week 68 at 2.4 mg, versus approximately 2.4% in the placebo group. What this means for someone at the 1.0 mg stage is that the medicine is already doing something, appetite signals are changing, gastric emptying is slowing, and some weight reduction is typically under way. If you want to understand what the 1 mg dose involves and how it fits into your treatment, that detail is worth reviewing before your next clinical check-in. The 1.0 mg dose is not a holding pattern; it is a functional part of the protocol. Researchers designed the step-up schedule to reduce gastrointestinal side effects during the adjustment period, which is why the dose increases are spaced roughly four weeks apart rather than starting at the top. Expecting 1.0 mg to produce the same results as 2.4 mg would misread what this dose is for: it is a deliberate bridge, not the destination.

Where 1.0 mg sits in the titration and why the pace matters

The full Wegovy dose schedule runs from 0.25 mg through to 2.4 mg, with 1.0 mg as the third of five steps, and a closer look at the mg strengths available across the range can help you understand what comes next after 1.0 mg. Each four-week increment gives the body time to adjust to semaglutide's effects on gut motility and appetite. Jumping this step (or extending it beyond the standard four weeks without clinical direction) is not something to decide independently. The NHS medicines page for semaglutide is clear that your prescriber sets the schedule; the Patient Information Leaflet in the box gives the same guidance. A practical thing worth doing: check the date on your current pen box against your expected dose-increase date before your next clinical review. It takes under a minute and means you are not guessing when the 1.7 mg pen should start. If you have questions about moving from 1.0 mg to the next step, your prescriber is the right person to ask, there are also specific questions around whether 1.0 mg might be an appropriate starting point in some clinical circumstances, which a prescriber would assess individually.

Side effects to be aware of at this dose

GI symptoms (nausea, loose stools, constipation, indigestion and burping) are most likely to surface after a dose increase, including the move to 1.0 mg. For most people these settle within the first week or two. If they persist or feel severe, contact your prescriber rather than reducing the dose yourself. A detailed look at side effects specific to the 1.0 mg dose covers what is typical, what warrants a call to your clinical team, and what is an urgent situation. One signal that always needs prompt medical attention: severe stomach pain that radiates to the back, with or without vomiting, this can indicate pancreatitis, which the MHRA highlighted in a January 2026 Drug Safety Update for GLP-1 medicines. It is uncommon but serious. Any suspected side effect can also be reported through the MHRA's Yellow Card scheme, which is open to patients as well as healthcare professionals. Injection-site reactions are mild and uncommon at this dose; rotating between the abdomen, thigh and upper arm helps reduce them.

Private access and clinical oversight at this stage of treatment

Wegovy is a prescription-only medicine at every dose, including 1.0 mg. The only lawful way to obtain it is through a prescription issued following a clinical assessment, this applies whether treatment is through the NHS or a private regulated pharmacy. For people who are not currently eligible for NHS provision or who would rather not wait, a private weight-loss treatment through a GPhC-registered service is a legitimate route, provided the pharmacy operates within the licensed supply chain and every prescription is issued by a qualified prescriber. If you are already on Wegovy 1.0 mg through a previous provider and are considering transferring, you would need to share evidence of your current treatment (dose, duration and any clinical notes) so a prescriber can review your full picture before issuing a new prescription. The cost of Wegovy through a private pharmacy is worth understanding clearly before starting; prices vary by dose and provider, and a transparent service should set out exactly what is included. Our clinical team reviews every consultation personally. If you are ready to talk through whether continuing or starting Wegovy is right for you, check your eligibility through a free consultation with one of our GPhC-registered Independent Prescribers.